• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharm (NQ: LGND )

    110.04 +4.34 (+4.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ligand Pharm

    < Previous 1 2 3 4 5 6 Next >
    Recap: Ligand Pharmaceuticals Q4 Earnings
    Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
    Via Benzinga
    Earnings Scheduled For February 17, 2022
    Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
    Via Benzinga
    The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
    Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
    Via Benzinga
    Ligand to Report Fourth Quarter Financial Results on February 17
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand and GSK Expand Global Collaboration and License Agreement
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Meme Stock Breakdown
    There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania. 
    Via Talk Markets
    Ligand Pharmaceuticals Sees RS Rating Rise To 92
    A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. 
    Via Investor's Business Daily
    Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company
    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb... 
    Via Benzinga
    Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript
    LGND earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Recap: Ligand Pharmaceuticals Q3 Earnings
    Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement.... 
    Via Benzinga
    Ligand Reports Third Quarter 2021 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
    Via Benzinga
    Ligand to Report Third Quarter Financial Results on November 9, 2021
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
    Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
    Via Benzinga
    Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals
    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC). The agreement grants... 
    Via Benzinga
    Exposures COVID-19
    Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Stock Shows Rising Price Performance
    A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance. 
    Via Investor's Business Daily
    Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating
    Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82. 
    Via Investor's Business Daily
    Why Digital Turbine's Stock Is Trading Higher Today
    Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400. Digital Turbine will replace ... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Digital Turbine Added To S&P MidCap 400 Index
    Media and mobile communications company Digital Turbine Inc (NASDAQ: 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
    Via Benzinga
    Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
    From Ligand Pharmaceuticals
    Via Business Wire
    What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months
    Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy... 
    Via Benzinga
    Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript
    LGND earnings call for the period ending June 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Ligand Reports Second Quarter 2021 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.